» Articles » PMID: 19104149

Infiltration of CD4+ Lymphocytes into the Brain Contributes to Neurodegeneration in a Mouse Model of Parkinson Disease

Abstract

Parkinson disease (PD) is a neurodegenerative disorder characterized by a loss of dopamine-containing neurons. Mounting evidence suggests that dopaminergic cell death is influenced by the innate immune system. However, the pathogenic role of the adaptive immune system in PD remains enigmatic. Here we showed that CD8+ and CD4+ T cells but not B cells had invaded the brain in both postmortem human PD specimens and in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD during the course of neuronal degeneration. We further demonstrated that MPTP-induced dopaminergic cell death was markedly attenuated in the absence of mature T lymphocytes in 2 different immunodeficient mouse strains (Rag1-/- and Tcrb-/- mice). Importantly, similar attenuation of MPTP-induced dopaminergic cell death was seen in mice lacking CD4 as well as in Rag1-/- mice reconstituted with FasL-deficient splenocytes. However, mice lacking CD8 and Rag1-/- mice reconstituted with IFN-gamma-deficient splenocytes were not protected. These data indicate that T cell-mediated dopaminergic toxicity is almost exclusively arbitrated by CD4+ T cells and requires the expression of FasL but not IFNgamma. Further, our data may provide a rationale for targeting the adaptive arm of the immune system as a therapeutic strategy in PD.

Citing Articles

Novel co-culture model of T cells and midbrain organoids for investigating neurodegeneration in Parkinson's disease.

Gerasimova E, Beenen A, Kachkin D, Regensburger M, Zundler S, Blumenthal D NPJ Parkinsons Dis. 2025; 11(1):36.

PMID: 40021643 PMC: 11871142. DOI: 10.1038/s41531-025-00882-8.


Ocular neuroinflammatory response secondary to SARS-CoV-2 infection-a review.

Zhao Y, Tang Y, Wang Q, Li J Front Immunol. 2025; 16:1515768.

PMID: 39967658 PMC: 11832381. DOI: 10.3389/fimmu.2025.1515768.


α-Synuclein orchestrates Th17 responses as antigen and adjuvant in Parkinson's disease.

Furusawa-Nishii E, Solongo B, Rai K, Yoshikawa S, Chiba A, Okuzumi A J Neuroinflammation. 2025; 22(1):38.

PMID: 39934862 PMC: 11816547. DOI: 10.1186/s12974-025-03359-w.


IMMUnity Unveiled: A Translational NETwork for tackling PARKinson's Disease - IMMUPARKNET.

Gugu M, Acharya S, Pira D, Poletti S, di Flora A, Saksida T Open Res Eur. 2025; 4:119.

PMID: 39911303 PMC: 11795026. DOI: 10.12688/openreseurope.17547.2.


FKBP51 inhibition ameliorates neurodegeneration and motor dysfunction in the neuromelanin-SNCA mouse model of Parkinson's disease.

Garcia-Gomara M, Garcia-Gomara M, Legarra-Marcos N, Legarra-Marcos N, Serena M, Serena M Mol Ther. 2025; 33(3):895-916.

PMID: 39905728 PMC: 11897814. DOI: 10.1016/j.ymthe.2025.01.049.


References
1.
Banerjee R, Mosley R, Reynolds A, Dhar A, Jackson-Lewis V, Gordon P . Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One. 2008; 3(7):e2740. PMC: 2481277. DOI: 10.1371/journal.pone.0002740. View

2.
McGeer P, Itagaki S, Akiyama H, McGeer E . Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol. 1988; 24(4):574-6. DOI: 10.1002/ana.410240415. View

3.
Takahashi T, Tanaka M, Brannan C, Jenkins N, Copeland N, Suda T . Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 1994; 76(6):969-76. DOI: 10.1016/0092-8674(94)90375-1. View

4.
Kortekaas R, Leenders K, van Oostrom J, Vaalburg W, Bart J, Willemsen A . Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol. 2005; 57(2):176-9. DOI: 10.1002/ana.20369. View

5.
Haussermann P, Kuhn W, Przuntek H, Muller T . Integrity of the blood-cerebrospinal fluid barrier in early Parkinson's disease. Neurosci Lett. 2001; 300(3):182-4. DOI: 10.1016/s0304-3940(01)01574-9. View